Category Archives: Healthcare

Market for CAR-T Cell Therapy

Cell Therapy

Aarkstore Enterprise culminates the newest Market Research Report “Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy.

In 2017, the world witnessed a historic CAR-T cell therapy approval when on August 30, 2017, Tisagenlecleucel (Kymriah) was approved by U.S. FDA for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). On May 1, 2018, FDA approved Kymriah for a second indication (diffuse large B-cell lymphoma). By October 18, 2017, the FDA granted approval for Yescarta for treating patients with relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL) and other rare large B-cell lymphomas. Other notable approvals for CAR-T cell therapy products have also been achieved.

In August 2018, Kymriah and Yescarta secured approval in Europe, indicating the willingness of European regulators to usher in a new age of regenerative medicine. Novartis’ Kymriah was given marketing authorization in the EU for the treatment of blood cancers, including B-cell acute lymphoblastic leukaemia (ALL) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Gilead/Kite Pharma’s Yescarta was authorized as a treatment for adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL). Health Canada approved Kymriah as the first CAR-T therapy in Canada and the Therapeutic Goods Administration (TGA) approved it as the first CAR-T therapy in Australia.

What is CAR-T Cell Therapy?

Chimeric antigen receptors (CARs) are genetically engineered cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer. The protein constructs stimulate anti-cancer T-cells, which in turn boost a patient’s immune system. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
CAR-T is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

How Does CAR-T Cell Therapy Work?

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Like all cancer therapies, CAR-T cell therapy can also cause a number of side effects. However, all these side effects can be managed with standard supportive therapies including steroids. The widespread research activities, worldwide clinical trials and treatments in a limited number of U.S. hospitals have created a robust CAR T-cell market. This billion dollar market and projected growth would have been not possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers.

Market for CAR-T Cell Therapy

CAR-T cell therapy has swept the biotech industry by storm in recent years, creating hope that it could welcome in a new age of cancer treatment. However, the remarkable success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive therapy space that is being shared between among leading CAR-T companies.

Scientists, investors and developers invariably agree that the key to longer-term success in this space depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products to deal with solid tumors will undoubtedly offer a larger market potential.

However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematical, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.

Currently, the only two non-CD19-directed CAR-T therapies are those that target CD22 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma. CD22 is structurally analogous to CD19, while BCMA is an antigen expressed on plasma cells, whose functional loss can also be replaced with IVIG.

The problem with solid tumors is that there is little evidence of CAR-T being able to overcome the numerous difficulties that exist for these to be targeted efficiently. However, both academic and commercial groups are racing against time to identify the antigens on solid tumor cells and develop suitable CAR-T cells, because it represents large market potential.
There are several reasons which make solid tumors difficult to treat using CAR-T cell therapies. Globally, solid tumors outnumber the hematological tumors by 10 to one. In 2015, Novartis and PENN reported that their CART-meso failed to show any effect in patients with mesothelioma, ovarian cancer and pancreatic cancer. Moreover, there was very poor persistence of CAR-T cells in the patients.

The difficulty with solid tumors is that they are usually surrounded by a hostile, immuno-suppressive microenvironment. This environment presents many inhibitory factors that prevent CAR-T cells from reaching them. A typical CAR-T approach will not have success under these conditions. For this reason, Juno and Novartis are engaging in constructing CAR-T cells with novel designs that incorporate additional elements to boost activity within this setting. Currently, these products are in preclinical development.

Driving Forces for the CAR-T Therapy Market

With growing demand for CAR-T therapies, CAR-T companies are proliferating. Growing numbers of these companies are supported by:
• Increasing investment flowing into CAR-T cell research
• Landmark approvals of CAR-T cell therapies by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA)
• Major acquisitions within the CAR-T industry
• Large IPOs within the CAR-T industry

As mentioned, 2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma developed Yescarta, a CAR-T therapy for patients with lymphomas. Approvals for these products are now spreading globally, with authorizations permitted by the EU, Canada, and Australia, among others. The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, both from regulators, as well as from the broader scientific and medical communities.
CAR-T funding is also on the rise. At first the trend was subtle, but the tide swelled as CAR-T therapies like Kymriah and Yescarta reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. Following IPOs by CAR-T players Kite Pharma, Bellicum, Juno Therapeutis and Cellectis totaling over $750 million, CAR-T developer Autolus announced a $150 million IPO.
This has bought the total value of recent CAR-T initial public offerings (IPO’s) to nearly $1 billion.

CAR-T Industry Deal-Making

The CAR-T industry has also witnessed aggressive deal-making in recent years. Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017. After $20 billion of market capitalization from the CAR-T companies in 2018, the CAR-T market has continued to gain momentum.
There have also been more than a dozen CAR-T deals between pharmaceutical companies and academic institutions, with the best known being the partnership between Novartis and the University of Pennsylvania (UPenn). When Kymriah™ because the first CAR-T cell therapy to be approved in the U.S. in August 2017, it resulted from a 5-year collaboration between UPenn and Novartis.

CAR-T financing rounds have also proliferated. In one major example, Celularity raised $250 million in February 2018 to support development of placental-derived products, including T-cells that will be immune advantaged because of their derivation from the placenta. Celularity is looking to burst a major bottleneck in the industry by deriving T-cells from a single (allogeneic) cell line, potentially positioning itself to slash the price point for CAR-T treatments. In other significant example, London-based CAR-T start-up Allogene Therapeutics entered into an asset contribution deal with Pfizer in April 2018, as well as announced a $300 million Series A round.

To better understand and compete within the rapidly expanding CAR-T marketplace, claim this global strategic report to learn the identities and strategies of leading market competitors, access market size data accompanied by market segmentation and forecasts, review clinical trial activity within the sector, assess CAR-T market approvals by region, and importantly, evaluate industry deal-making, emerging technologies, and future directions for the industry at large.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Advertisements

Global Animal Health Market Research Report , Growth and Forecast

animal health

Aarkstore Enterprise announced latest Market Research Report Titled “Global Animal Health Market

Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Animal Health Market. The study on global animal health market has been analyzed By Type (Farm animal, Companion animal), By Product (Biologicals, Pharmaceuticals, Feed additives), By Route of drug administration (Oral, Parenteral, Topical, Transdermal) and By Distribution Channel (Retail, E-commerce, Veterinary Hospital, Clinic). The study on global animal health market has been analyzed By Region (North America, Europe, Asia Pacific, Rest of the world) and By Country (U.S, Canada, Germany, U.K, Italy, China, India and Mexico). The study assesses the animal health market for the historical period of 2013-2017 and the forecast period of 2018-2023.

According to the research report, “Global Animal Health Market: Analysis By Type (Farm, Companion), By Products (Biologicals, Pharmaceuticals, Feed Additives), By Route of drug administration (Oral, Parenteral, Topical, Transdermal), By Distribution Channel (Retail, E-commerce, Veterinary Hospital, Clinic), By Region, By Country: Opportunities and Forecast (2013-2023)”, the global animal health market is projected to display a high growth represented by a CAGR of 5.63% during 2018 – 2023.

Over the recent years, global animal health market has been witnessing growth, on account of several driving factors including increase in protein demand, increase in pet ownership rates, rising incidences of zoonotic disease and changing lifestyle of the people favouring individualism. Moreover heightening focus on food safety, increasing focus on animal welfare, growing scope in emerging markets and consolidation of the market is expected to propel the demand for animal health. In this research report, the market is segmented on the basis of type, product, route of drug administration as well as distribution channel. By type, farm animal is predicted to hold its dominant position in the market, but companion animals are growing at a faster rate. Amongst the regions, North America accounts for the largest regional share in the global animal health market in 2018. However, Asia Pacific is predicted to advance at the highest rate. Presence of vast consumer base, particularly in emerging nations such as China and India, in addition to growing per capita expenditure on pets is likely to drive the regional market.

The report titled “Global Animal Health Market: Analysis By Type (Farm, Companion), By Products (Biologicals, Pharmaceuticals, Feed Additives), By Route of drug administration (Oral, Parenteral, Topical, Transdermal), By Distribution Channel (Retail, E-commerce, Veterinary Hospital, Clinic), By Region, By Country: Opportunities and Forecast (2013-2023)” has covered and analyzed the potential of global animal health market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global animal health market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Animal Health Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Animal Health Market – Size, Growth, Forecast
• By Type- Farm Animal, Companion Animal
• By Product – Biologicals, Pharmaceuticals, Feed additives
• By Route of Drug Administration- Oral, Parenteral, Topical and Transdermal
• By Distribution Channel – Retail, E-commerce, Veterinary Hospital and Clinic

Regional Market – North America, Europe, Asia-Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Animal Health Market – Size, Growth, Forecast
• By Type- Farm Animal, Companion Animal
• By Product – Biologicals, Pharmaceuticals, Feed additives
• By Route of Drug Administration- Oral, Parenteral, Topical and Transdermal
• By Distribution Channel – Retail, E-commerce, Veterinary Hospital and Clinic

Country Analysis – U.S., Canada, Germany, U.K, Italy, India, China, Mexico (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Animal Health Market – Size, Growth, Forecast
• By Type- Farm Animal, Companion Animal
• By Product – Biologicals, Pharmaceuticals, Feed additives
• By Route of Drug Administration- Oral, Parenteral, Topical and Transdermal
• By Distribution Channel – Retail, E-commerce, Veterinary Hospital and Clinic

Other Report Highlights
• Market Dynamics – Drivers and Restraints
• Market Trends
• Competitive Analysis
• SWOT Analysis
• Porter Five Force Analysis
• Supply Chain Analysis
• Policy and Regulatory Landscape
• Company Analysis – Alivira Animal Health Limited, Boehringer Ingelheim, Zoetis, Elanco, Merck Animal Health, Chr. Hansen, Phibro Animal Health Corporation, ECO Animal Health, Bayer Animal Health, Dechra Pharmaceuticals.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Development of US and Chinese Retail Giants in the Healthcare Sector | Aarkstore

Retail Healthcare Sector

Aarkstore Market Research published the new epoch of Market Research Report “Development Of US And Chinese Retail Giants In The Healthcare Sector

Since the end of 2017, several leading international retailers have conducted acquisitions and initiated investments in attempts to tap into the growing healthcare industry. The healthcare industry generally comprises of medical, pharmaceutical, and insurance components. This report provides an overview of acquisitions and investment plans of four retail giants: CVS Health, Walgreens, Amazon, and Alibaba in the healthcare space, outlines their existing healthcare landscape and advantages, and analyzes their strategies to drive their business in this arena.

  1. Development of retail brands in Healthcare sector
    1.1 Primary Healthcare Services Only
    1.2 Traditional Companies vs. Startups
    2. RetaiL brands Existing Healthcare Landscape
    3. Deployment strategies
    3.1 CVS Aims for Business Diversification by Integrating Medical, Pharmaceutical, and Insurance Services
    3.2 Walgreens Adds Telemedicine Services to Enhance Existing Medical Care Services
    3.3 Amazon Enters Medical Care Service for the First Time to Capture the Seniors Market
    3.4 Alibaba Aims to Deepen Presence in O2O Prescription Drug Services
    MIC Perspective
    Prescription Drugs and Medical Insurance are the Areas of Focus for Retail Giants
    Creating Service Differentiation is Key to Success
    Appendix
    Glossary of Terms
    List of Companies
    List of Tables
    Table 1 Overview of M&As of International Retail Giants
    Table 2 Self-operated Healthcare Service of Amazon and Walgreens
    Table 3 Retail Brands Deployment in the Healthcare Sector
    List of Figures
    Figure 1 Retail Giants Strategies for Healthcare Market Expansion

    List Of Tables

    Development of retail brands in the healthcare sector, touching on their main service types and the comparison between traditional companies and startups in this arena
    Retail brands existing healthcare landscape and includes their M&A activities in recent years
    Deployment strategies of leading retail brands such as CVS, Walgreen, Amazon, and Alibaba

    List Of Figures

    Figure 1 Retail Giants Strategies for Healthcare Market Expansion

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog

Global Blood Plasma Market Opportunities and Forecast (2013-2023) | Aarkstore

Blood Plasma

Aarkstore Enterprise announced latest Market Research Report Titled “Global Blood Plasma Market Opportunities and Forecast (2013-2023)

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis Global Blood Plasma Market. The report analyses the Blood Plasma Market By Type (Immunoglobulins- IV+SC, Albumin, Factor VIII- Plasma Derived, and Others), By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S, Canada, Germany, France, Italy, China, Japan, India, Australia, and South-East Asia). The report on Blood Plasma assesses the market for the actual period of 2013-2017 and the forecast period of 2018-2023.

According to the research report “Global Blood Plasma Market – Analysis By Type (Immunoglobulins – IV+SC, Albumin, Factor VIII – Plasma Derived), By Region, By Country (2018 Edition): Opportunities and Forecast (2013-2023)”, the global blood plasma market is projected to display a robust growth represented by a CAGR of 10.18% during 2018 – 2023.

The Blood Plasma market witness a substantial growth at a noteworthy rate over the past few years and anticipated to grow on the back of its increasing usage in plasma-derived medical products. In addition, rise in awareness towards plasma donation, rise of China blood plasma industry, introduction of new and specialized products, rising geriatric population, rapid increase of the healthcare expenditure on the diseases such as immunodeficiency, neurological disorders, clotting disabilities etc. anticipated to boost the market growth in future. Amongst the regions, North America accounts for the largest regional share in the global blood plasma market. Key factor driving the robust growth rate in North America region is collection of source plasma in large volume for the fractionation process.

The report titled “Global Blood Plasma Market – Analysis By Type (Immunoglobulins – IV+SC, Albumin, Factor VIII – Plasma Derived), By Region, By Country (2018 Edition): Opportunities and Forecast (2013-2023)” has covered and analysed the potential of Global Blood Plasma Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global blood ingredients market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Blood Plasma Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market – Size, Growth, Forecast
• Analysis By Type- Size, Volume, Growth, Forecast
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)

Regional Markets – North America, Europe, Asia Pacific, and Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market – Size, Growth, Forecast
• Analysis By Type
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)

Country Analysis – U.S., Canada, Germany, France, Italy, China, Japan, India, Australia, and South-East Asia. (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market – Size, Growth, Forecast
• Analysis By Type
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)

Other Report Highlights
• Market Dynamics – Drivers and Restraints
• Market Trends
• Porter Five Forces Analysis
• Company Analysis – CSL Limited, Baxter International, Grifols S.A, Octa Pharma, Emergent Bio-solutions, Antaris Pharma, AMAG Pharma, Biota Pharma, Bio delivery Science International, Biotest A.G.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog

 

Pharmaceuticals and Healthcare – Autoimmune Drugs Markets in China

Autoimmune Drugs

Chinas demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines Chinas economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled.

The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars.

Our market research reports provide hard-to-find market data and analyses. Today, China has the largest market in the world. Tremendous fast-growing markets for imports and business opportunities for companies around the world. If you want to expand your business or sell your products in China, our research reports provide the insights and projections into Chinese markets necessary for you to do so.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Autoimmune Drugs Companies in China

Global Autoimmune Disease Diagnosis Market Professional Survey Report 2018

Global Autoimmune Partnering 2012-2018: Deal trends, players and financials

Global Autoimmune Disorders Treatment Market Research Report 2016

Autoimmune Technologies, LLC Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

 

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: http://www.aarkstore.com
Our blog: http://www.aarkstore.com/blog

 

Global Immunology Market Size and Revenue Forecasts

ImmunologySummary
Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

Request for Sample Market Report @http://www.aarkstore.com/sample/184047

Scope
Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
– What factors are driving the market growth?
– How can the factors limiting growth be overcome?
There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
– What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
– How does the composition of the pipeline compare with that of the existing market?
Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
– How will this affect their revenues in this period?
– How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?

Reasons to buy market research
This report will allow you to –
– Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
– Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
– Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
– Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
– Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders

Related Market Research Reports :

About Aarkstore:

Aarkstore Enterprise is among global marketing research companies involved in selling market reports across different industries and countries. We help serve thousands of clients annually with syndicated, custom market research and consulting. Collaborating with renowned market research partners, we have continued to etch our presence as an established as channel sales partner of market research intelligence on various frontiers. Clients from all sectors, including public, private, and commercial are endowed with best data modelling and processing structures with custom reports.

For further details, please Contact Us

Hepatitis A Virus Cellular Receptor 2-Pipeline Review, H1 2017

Hepatitis A Virus Cellular Receptor 2Summary
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) – Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance.

Request for Sample Market Report @http://www.aarkstore.com/sample/521276

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
– The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
– The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects
– The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects

Reasons to buy market report
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

Related Market Research Reports :

Asia-Pacific Ebola Virus Vaccine Market Report 2017

Global Zika Virus Market Research Report 2017

Autoimmune Hepatitis Global Clinical Trials Review, H1, 2017

About Aarkstore:

Aarkstore Enterprise is among global marketing research companies involved in selling market reports across different industries and countries. We help serve thousands of clients annually with syndicated, custom market research and consulting. Collaborating with renowned market research partners, we have continued to etch our presence as an established as channel sales partner of market research intelligence on various frontiers. Clients from all sectors, including public, private, and commercial are endowed with best data modelling and processing structures with custom reports.

For further details, please Contact Us

%d bloggers like this: